市場調查報告書
商品編碼
1395618
細胞冷凍保存全球市場規模、佔有率、產業趨勢分析報告:2023-2030 年按組件、最終用途和地區分類的展望和預測Global Cell Cryopreservation Market Size, Share & Industry Trends Analysis Report By Component, By End-use, By Application (Stem Cells, Oocytes & Embryotic cells, Sperm Cells, Hepatocytes), By Regional Outlook and Forecast, 2023 - 2030 |
預計到 2030 年,細胞冷凍保存市場規模將達到 357 億美元,預測期內市場成長率為 20.3%。
根據 KBV Cardinal 矩陣中發表的分析,Thermo Fisher Scientific Inc 和 Danaher Corporation 是市場先驅。 2023年8月,賽默飛世爾科技推出TSV系列實驗室冰箱和冷凍庫。推出的產品均提供溫度控制技術,包括超低溫冷凍櫃和冷凍儲存槽,確保溫度均勻性和穩定性,降低樣品劣化風險。 Sartorius AG、Lonza Group AG 和 Merck KGAA 等公司是該市場的主要創新者。
COVID-19 影響分析
COVID-19大流行對市場產生了重大影響。這場大流行導致與該病毒相關的研究激增,包括患者樣本的收集和儲存。這增加了對低溫保存服務和設施的需求。 COVID-19 疫苗的快速開發需要廣泛的研究和測試。因此,越來越需要保存疫苗開發中使用的細胞株和材料。這場大流行凸顯了為未來健康危機做好準備的重要性。各國政府和組織已經認知到需要裝備精良的生物樣本庫和低溫保存基礎設施來有效應對未來的大流行,並鼓勵在這些領域進行投資。這導致了更先進、更有效率的冷凍保存技術和設備的發展。
市場成長要素
增加卵子冷凍週期
人們對卵子冷凍的興趣日益濃厚,對生育診所、體外受精中心和生殖醫學專家提供的冷凍保存服務的需求也隨之增加。這些設施需要必要的基礎設施,包括冷凍保存設備和專業知識,以提供卵子冷凍服務。對卵子冷凍的需求不斷成長,刺激了冷凍保存技術和設備的技術進步。卵子冷凍庫是卵子冷凍市場不可或缺的一部分,依靠專門的冷凍保存解決方案和設備來維持冷凍卵子的品質和活力。卵子冷凍週期的擴大有助於市場成長。
生物庫的增加和個體化藥物的需求
全球生物樣本庫的建立和擴散對細胞冷凍保存服務產生了巨大的需求。這些生物庫依靠冷凍保存技術來保存和保存各種生物樣本以供研究和臨床使用。個人化醫療根據個別患者的遺傳和特定需求提供量身定做的醫療護理,並且通常需要獲得保存完好的生物樣本。冷凍保存的樣本可識別與多種疾病、藥物反應和治療結果相關的遺傳標記和生物標記。生物樣本庫的增加和對個體化藥物的需求正在擴大市場。
市場抑制因素
細胞冷凍保存替代療法的可用性
替代方案的成本效益和可用性會影響其採用。如果替代方案更便宜或需要較少的專業設備,則在某些情況下可能會變得普及。採用替代冷凍保存方法可能取決於提高意識並教育研究人員和臨床醫生了解其好處和正確使用。檢驗冷凍保存替代方案的有效性和安全性是一個複雜的過程。替代方案可以與微流體和 3D 生物列印等其他技術和方法相結合,從而有可能改變低溫保存市場的面貌。這些因素可能會降低未來幾年的市場成長。
組件展望
根據成分,市場分為細胞冷凍介質、設備和消耗品。 2022年,消耗品部門以最大的銷售佔有率主導市場。細胞凍存消耗品對於超低溫保存和儲存細胞和組織至關重要,通常儲存在液態氮或超低溫冰箱中。這主要是由於最終用戶擴大採用冷凍管、冷凍管和其他消耗品,因為它們具有污染少等優點。推動該行業成長的其他因素包括慢性病的增加、對生技藥品的需求不斷成長以及最終用戶對冷凍保存的需求不斷成長。
消耗品前景
依消耗品類型,市場進一步細分為低溫瓶、低溫管、冷卻箱/容器等。 2022 年,低溫瓶細分市場佔據市場最高收益佔有率。低溫瓶由耐極冷的材料製成,確保保持樣品的完整性。這有助於研究人員有效地定位和檢索特定樣本。低溫瓶設計用於承受極端溫度,並且可以在低溫環境中安全使用。保護研究人員和實驗室人員免受極低溫度的影響。
細胞冷凍介質的展望
根據細胞冷凍介質類型,市場進一步細分為乙二醇、二甲基亞碸、甘油等。 2022年,乙二醇細分市場收益佔有率最高。乙二醇透過進入細胞並抑製結晶的形成而充當冷凍保護劑。這對於細胞的存活很重要。冷凍介質中乙二醇的濃度可以根據特定方案和儲存的細胞類型而變化。濃度經過精心選擇,可提供有效的冷凍保護,同時最大限度地減少潛在毒性。
設備展望
按設備類型,市場進一步細分為冷凍機、培養箱和液態氮供應罐。 2022年,冰櫃領域佔據了市場上最大的收益佔有率。冰箱透過提供在超低溫下保存生物樣本(包括細胞、組織和其他生物材料)所需的儲存條件,在市場上發揮重要作用。冰箱是市場上必不可少的工具,可確保長期保存有價值的生物樣本,以促進科學和醫學進步。
最終用途展望
根據最終用途,市場分為生物製藥和製藥公司、研究機構、生物銀行、體外受精診所等。在2022年的市場中,生物樣本庫產業獲得了很大的收益佔有率。生物樣本庫對於儲存和保存生物樣本(包括組織和細胞)以用於研究和臨床應用至關重要。根據國家醫學圖書館的數據,到 2022 年,經濟已開發國家每百萬人將擁有至少 11 個生物樣本庫。其目標是簡化國際生物樣本庫的連接,並實現更大規模、更穩健的基因資料研究。該計劃旨在透過增加更多的遺傳祖先多樣性來增加檢測新的疾病相關遺傳變異的可能性。
應用前景
依應用,市場分為幹細胞、卵子/胚胎細胞、精子細胞、肝細胞等。到2022年,幹細胞領域將佔據市場最大的收益佔有率。幹細胞應用在很大程度上依賴細胞冷凍保存,它可以在不改變細胞或基因的情況下保存、儲存和運輸幹細胞。根據世界衛生組織(WHF)2023年的記錄,全球有超過5億人受到心血管疾病(CVD)的影響,2021年將有約2050萬人死亡,導致全球整體死亡人數最高。接近總數的三分之一。不斷成長的老年人口,加上久坐的生活方式,將增加心血管疾病的負擔,並刺激該行業的更大成長。
區域展望
從區域來看,我們對北美、歐洲、亞太地區和拉丁美洲/中東/非洲的市場進行了分析。 2022 年,亞太地區在市場中取得了顯著的收益佔有率。這是由於亞太地區,特別是中國和日本擴大採用細胞冷凍保存技術。該地區人口眾多、慢性病多發、老年人口增加、不孕症比例快速上升,市場拓展空間廣大。
The Global Cell Cryopreservation Market size is expected to reach $35.7 billion by 2030, rising at a market growth of 20.3% CAGR during the forecast period.
The surge in stem cell research has led to a growing demand for the banking of various types of stem cells, including embryonic stem cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells. Therefore, Stem Cells segment generated $3,228.6 million revenue in the market in 2022. As a result, the increasing focus on stem cell research has driven innovations in cryopreservation techniques specifically tailored to the needs of different stem cell types. These advancements have improved the viability and functionality of cryopreserved stem cells, expanding the capabilities of the market.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, BioLife Solutions, Inc. unveiled IntelliRate i67C, a new, large-capacity controlled-rate freezer. This launch aimed to fulfill a crucial customer requirement for higher volume production of cell therapies. Moreover, In January, 2021, Lonza Group AG released cryopreserved Leukopaks, an expansion in renowned human primary cell offerings. The launched product would allow long-distance transportation of leukapheresis products without the concern of decreased cell viability encountered with fresh Leukopaks.
Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific Inc and Danaher Corporation are the forerunners in the Market. In August, 2023, Thermo Fisher Scientific Inc. launched the TSV series of laboratory refrigerators and freezers, the Made in India. The launched product would offer controlled temperature technologies including ultra-low temperature freezers and cryopreservation storage tanks that guarantee temperature uniformity and stability, mitigating the risk of sample degradation. Companies such as Sartorius AG, Lonza Group AG and Merck KGAA are some of the key innovators in the Market.
COVID-19 Impact Analysis
The COVID-19 pandemic had a substantial impact on the market. The pandemic led to a surge in research related to the virus, including the collection and storage of patient samples. This increased demand for cryopreservation services and facilities. The rapid development of COVID-19 vaccines required extensive research and testing. This, in turn, led to an increased need for the preservation of cell lines and materials used in vaccine development. The pandemic highlighted the importance of preparedness for future health crises. Governments and organizations recognized the need for well-equipped biobanking and cryopreservation infrastructure to respond effectively to future outbreaks, which drove investment in these areas. This led to the development of more advanced and efficient cryopreservation techniques and equipment.
Market Growth Factors
Increasing number of egg-freezing cycles
The rising interest in egg freezing has increased the demand for cryopreservation services provided by fertility clinics, IVF centers, and reproductive medicine specialists. These facilities require the necessary infrastructure, including cryopreservation equipment and expertise, to offer egg-freezing services. The growing demand for egg freezing has spurred technological advancements in cryopreservation techniques and equipment. These banks are an integral part of the market, and they rely on specialized cryopreservation solutions and equipment to maintain the quality and viability of frozen eggs. The expansion of egg-freezing cycles has contributed to the growth of the market.
Growing number of biobanks and demand for personalized medicines
The establishment and growth of biobanks worldwide have created a significant demand for cell cryopreservation services. These biobanks rely on cryopreservation techniques to store and preserve diverse biological samples for research and clinical use. Personalized medicine, which tailors medical treatments to individual patients based on their genetics and specific needs, often requires access to well-preserved biological samples. Cryopreserved samples identify genetic markers and biomarkers associated with multiple diseases, drug responses, and treatment outcomes. The increasing number of biobanks and the demand for personalized medicines have expanded the market.
Market Restraining Factors
Availability of alternative therapies for cell cryopreservation
The cost-effectiveness and accessibility of alternative methods can influence their adoption. If alternative methods are more affordable or require less specialized equipment, they may gain popularity in specific contexts. Adopting alternative cryopreservation methods may depend on raising awareness and educating researchers and clinicians about their benefits and proper usage. Validating the effectiveness and safety of alternative methods for cryopreservation can be a complex process. Alternative methods may be integrated with other technologies or approaches, such as microfluidics or 3D bioprinting, which could change the landscape of the cryopreservation market. These factors will decline the market growth in the coming years.
Component Outlook
On the basis of component, the market is segmented into cell freezing media, equipment, and consumables. In 2022, the consumables segment dominated the market with the maximum revenue share. Cell cryopreservation consumable products are essential in preserving and storing cells and tissues at very low temperatures, typically in liquid nitrogen or ultra-low temperature freezers. This is primarily due to factors such as the increasing adoption of cryovials, cryotubes, and other consumables by end-users due to benefits such as lower contamination. Other aspects, including the rising majority of chronic diseases, growing demand for biologics, and rising demand for cryopreservation among end-users, will propel the segment's growth.
Consumables Outlook
Under consumables type, the market is further segmented into cryogenic vials, cryogenic tubes, cooler boxes/containers, and others. In 2022, the cryogenic vials segment held the highest revenue share in the market. Cryogenic vials are made of materials that are highly resistant to extreme cold, ensuring the preservation of sample integrity. This helps researchers efficiently locate and retrieve specific samples. Cryogenic vials are designed to withstand extreme temperatures and are safe for use in cryogenic environments. They protect researchers and laboratory personnel from exposure to ultra-low temperatures.
Cell Freezing Media Outlook
Under cell freezing media type, the market is further divided into ethylene glycol, dimethyl sulfoxide, glycerol, and others. In 2022, the ethylene glycol segment registered the highest revenue share in the market. Ethylene glycol acts as a cryoprotective agent by entering the cells and reducing ice crystal formation. This is important for cell survival. The concentration of ethylene glycol in freezing media can change depending on the specific protocol and the preserved cell type. The concentration is carefully chosen to provide effective cryoprotection while minimizing potential toxicity.
Equipment Outlook
Under equipment type, the market is further classified into freezers, incubators, and liquid nitrogen supply tanks. In 2022, the freezers segment generated the largest revenue share in the market. Freezers play a critical role in the market by providing the necessary storage conditions for preserving biological samples, including cells, tissues, and other biological materials, at ultra-low temperatures. They are vital tools in the market, ensuring the long-term preservation of valuable biological materials for scientific and medical advancements.
End-use Outlook
By end-use, the market is categorised into biopharmaceutical & pharmaceutical companies, research institutes, biobanks, IVF clinics, and others. The biobanks segment garnered a significant revenue share in the market in 2022. Biobanks are critical in the storage and preservation of biological samples, including tissues and cells, for research and clinical applications. According to the National Library of Medicine, economically developed countries had at least 11 biobanks per million people in 2022. Its goal is to simplify the connection of international biobanks, enabling larger and more robust genetic data investigations. This program intends to increase the possibility of detecting novel disease-associated genetic variations by adding more genetic ancestral variety.
Application Outlook
Based on application, the market is fragmented into stem cells, oocytes & embryotic cells, sperm cells, hepatocytes, and others. In 2022, the stem cells segment witnessed the largest revenue share in the market. Stem cell applications rely heavily on cell cryopreservation, which allows stem cells to be preserved, stored, and transported without cellular or genetic change. As per the World Health Federation- 2023 records, over half a billion people worldwide are affected by cardiovascular disorders (CVDs), with around 20.5 million deaths occurring in 2021, accounting for nearly one-third of all deaths globally. The growing senior population, combined with sedentary lifestyles, will raise the burden of cardiovascular disease, fueling the expansion of the segment growth.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region recorded a remarkable revenue share in the market in 2022. Due to the rising adoption of cell cryopreservation technologies in the Asia Pacific region, especially throughout China and Japan. Because of the region's large population, the prevalence of chronic diseases, the rising number of older people, and the surge in the rate of infertility, there is enough scope for expanding the market in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., Sartorius AG, PromoCell GmbH, Lonza Group Ltd., HiMedia Laboratories Pvt. Ltd., Corning Incorporated, BioLife Solutions, Inc., Eppendorf SE and Danaher Corporation.
Recent Strategies Deployed in Cell Cryopreservation Market
Mergers & Acquisition
Jul-2023: Sartorius AG acquired Polyplus, a leading provider of innovative technologies for cell and gene therapies. Through this acquisition, both companies aimed to widen their focus in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening their suites for gene therapies as well as gene-modified cell therapies.
Jul-2021: Sartorius AG took over Xell AG, an innovative partner for the biotech and pharmaceutical industry. This acquisition aimed to widen Sartorius's current media portfolio specifically by specialized media for manufacturing viral vectors and in the area of media analytics.
Mar-2020: Eppendorf AG took over Koki Holdings Co., Ltd., a Japan-based power/air tool manufacturer. This acquisition aimed to widen the Eppendorf centrifuge business and solidify its strong market position as one of the world's leading makers of high-end centrifuges for the pharma and life science industries including academic and commercial research.
Nov-2019: BioLife Solutions, Inc. acquired Custom Biogenic Systems, Inc., a privately held company with operations located near Detroit. This acquisition aimed to deepen engagement with BioLife Solutions cell and gene therapy customers and increase touchpoints in their manufacturing, storage, and distribution workflows.
Product Launches and Product Expansions
Aug-2023: Thermo Fisher Scientific Inc. launched the TSV series of laboratory refrigerators and freezers, the Made in India. The launched product would offer controlled temperature technologies including ultra-low temperature freezers and cryopreservation storage tanks that guarantee temperature uniformity and stability, mitigating the risk of sample degradation.
Jun-2023: BioLife Solutions, Inc. unveiled IntelliRate i67C, a new, large-capacity controlled-rate freezer. This launch aimed to fulfill a crucial customer requirement for higher volume production of cell therapies.
Oct-2022: Thermo Fisher Scientific Inc. introduced the new Gibco CTS DynaCellect Magnetic Separation System, to improve the cell therapy manufacturing process. The launched product would enable customers to commercialize therapies faster and potentially save more lives.
Apr-2021: BioLife Solutions, Inc. introduced a new suite of high-capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company. The launched product would be a critical component in the customer's cold chain management of several allogeneic cell therapies in development.
Jan-2021: Lonza Group AG released cryopreserved Leukopaks, an expansion in renowned human primary cell offerings. The launched product would allow long-distance transportation of leukapheresis products without the concern of decreased cell viability encountered with fresh Leukopaks.
May-2020: Sartorius AG unveiled the Incucyte SX5 Live-Cell Analysis System, the latest in the company's portfolio of live-cell analysis products. The launched product would provide new capabilities, including novel optics, a new line of paired reagents, and purpose-built software to allow researchers to draw greater insight from each live cell experiment.
Partnerships, Collaborations & Agreements
Jul-2023: Sartorius AG came into collaboration with Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins. This collaboration aimed to allow rapid advancement in the science of advanced cell models.
Jun-2023: Sartorius AG collaborated with Stanford University, the leading research and teaching institution. This collaboration aimed to develop a Scalable Platform for Large-Scale Human iPSC Production.
Dec-2021: Sartorius AG partnered with HOF Sonderanlagenbau, a machinery company that manufactures freeze-drying, loading and unloading systems, freezing and thawing devices. This partnership aimed to empower Sartorius AG's leading position in the freeze-thaw market.
Dec-2021: Lonza Group AG collaborated with Agilent Technologies, a leader in life sciences analytics, diagnostics, and applied chemical markets. This collaboration aimed to change the way personalized cell therapies are manufactured and realized.
Jan-2021: Sartorius AG collaborated with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks. This collaboration aimed to scale of hMSC manufacturing for regenerative medicine by leveraging the best-in-class solutions of both companies to significantly decrease process development efforts.
Expansion
Jul-2023: Sartorius AG opened a cell culture media manufacturing facility in Yauco, Puerto Rico. The new facility would widen the company's cell culture media capacities, with a focus on customers in the Americas region.
Market Segments covered in the Report:
By Component
By End-use
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research